Himadri Speciality Chemical Ltd reports record Q1FY27 revenue and profit
Himadri Speciality Chemical · Chemicals & Petrochemicals
Key highlights
- Q1FY27 consolidated revenue ₹1,432 Cr (+28%), EBITDA ₹313 Cr (+33%), PAT ₹228 Cr (+27%)
- Announced two growth projects: 200 MTPA Carbon Nanotube facility (₹70 Cr capex) by Q4FY27, and 6,000 MTPA Super Speciality Carbon Black project (₹170 Cr capex) by Q4FY28
- Expanded New Energy Materials with 200 MTPA anode facility commissioned April 2026 and 2,000 MTPA LFP Cathode Active Materials facility targeted for Q3FY27 commissioning
Why it's rated notable: the year-on-year change is 27% (20% to 50%)
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Himadri Speciality Chemical
- Capex / expansionNotableHimadri Speciality Chemical Ltd announces Q1 FY27 financials and business updates
- Capex / expansionNotableHimadri Speciality Chemical Ltd starts first anode material production facility
- Dividend / buyback / bonusNotableHimadri Speciality Chemical Ltd announces FY 2026 audited results and new subsidiary plans
- Dividend / buyback / bonusNotableHimadri Speciality Chemical Ltd announces FY 2025-26 audited results and dividend proposal
- Capex / expansionNotableHimadri Speciality Chemical Ltd Reports Record FY26 Results and New Facility Launches
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.